RSS Feeds
Dapsone in Thrombocytopenia of the Antiphospholipid Antibody Syndrome
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
IN RESPONSE:
Lesprit and colleagues report the potential steroid-sparing effect of dapsone for the treatment of thrombocytopenia in a patient with the antiphospholipid antibody syndrome. As with danazol, dapsone has also previously been used successfully to treat idiopathic immune thrombocytopenia. Although the mechanisms underlying thrombocytopenia in these two conditions may differ, several therapies that have been successful in treating idiopathic immune thrombocytopenia might be useful in treating thrombocytopenia associated with antiphospholipid antibodies. Expanding the scope of potential therapies for this disorder could provide substantial benefits to affected patients by modifying the risks associated with prolonged use of corticosteroids.
Arthur Kavanaugh
- Copyright ©2004 by the American College of Physicians
